2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 125

Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic
Abstract Number: 110

Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Abstract Number: 111

Monitoring for Hypogammaglobulinemia After B-Cell Therapy in an Academic Pediatric Center
Abstract Number: 128

Multisystem Inflammatory Syndrome in Children and Systemic Juvenile Idiopathic Arthritis Share Clinical Phenotypes and Genetic Contributions
Abstract Number: 031

Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Abstract Number: 072

Musculoskeletal Ultrasound Findings in Children with Psoriasis
Abstract Number: 022

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias
Abstract Number: 069

Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus
Abstract Number: 068

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Abstract Number: 045

Patient Reported Outcomes in Pediatric Vasculitis
Abstract Number: 025

Patient- and Center-level Risk Factors for Research Lost to Follow-up Using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 134

Patient-Provider Communication in Pediatric Rheumatology
Abstract Number: 026

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort
Abstract Number: 078

Periodic Fever Syndrome and Myelodysplastic Syndrome: Possible Connections Between Two Disorders
Abstract Number: 017

Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].